225 related articles for article (PubMed ID: 15592323)
1. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
2. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; McLeod HL; Yokoi T
Biochem Pharmacol; 2005 Sep; 70(5):801-8. PubMed ID: 15993850
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495
[TBL] [Abstract][Full Text] [Related]
5. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
Peamkrasatam S; Sriwatanakul K; Kiyotani K; Fujieda M; Yamazaki H; Kamataki T; Yoovathaworn K
Drug Metab Pharmacokinet; 2006 Dec; 21(6):475-84. PubMed ID: 17220563
[TBL] [Abstract][Full Text] [Related]
6. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T
Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137
[TBL] [Abstract][Full Text] [Related]
7. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.
Ho MK; Mwenifumbo JC; Zhao B; Gillam EM; Tyndale RF
Pharmacogenet Genomics; 2008 Jan; 18(1):67-75. PubMed ID: 18216723
[TBL] [Abstract][Full Text] [Related]
8. Nicotine metabolism and CYP2A6 allele frequencies in Koreans.
Kwon JT; Nakajima M; Chai S; Yom YK; Kim HK; Yamazaki H; Sohn DR; Yamamoto T; Kuroiwa Y; Yokoi T
Pharmacogenetics; 2001 Jun; 11(4):317-23. PubMed ID: 11434509
[TBL] [Abstract][Full Text] [Related]
9. Determination of coumarin metabolism in Turkish population.
Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S
Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269
[TBL] [Abstract][Full Text] [Related]
10. Novel human CYP2A6 alleles confound gene deletion analysis.
Nakajima M; Yoshida R; Fukami T; McLeod HL; Yokoi T
FEBS Lett; 2004 Jul; 569(1-3):75-81. PubMed ID: 15225612
[TBL] [Abstract][Full Text] [Related]
11. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
12. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T
Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685
[TBL] [Abstract][Full Text] [Related]
13. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
Paschke T; Riefler M; Schuler-Metz A; Wolz L; Scherer G; McBride CM; Bepler G
Toxicology; 2001 Nov; 168(3):259-68. PubMed ID: 11684323
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
Mwenifumbo JC; Lessov-Schlaggar CN; Zhou Q; Krasnow RE; Swan GE; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2008 Jan; 83(1):115-21. PubMed ID: 17522595
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
Yoshida R; Nakajima M; Watanabe Y; Kwon JT; Yokoi T
Br J Clin Pharmacol; 2002 Nov; 54(5):511-7. PubMed ID: 12445030
[TBL] [Abstract][Full Text] [Related]
17. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.
Inoue K; Yamazaki H; Shimada T
Arch Toxicol; 2000 Jan; 73(10-11):532-9. PubMed ID: 10663384
[TBL] [Abstract][Full Text] [Related]
18. A novel duplication type of CYP2A6 gene in African-American population.
Fukami T; Nakajima M; Yamanaka H; Fukushima Y; McLeod HL; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):515-20. PubMed ID: 17267622
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity.
Oscarson M; McLellan RA; Asp V; Ledesma M; Bernal Ruiz ML; Sinues B; Rautio A; Ingelman-Sundberg M
Hum Mutat; 2002 Oct; 20(4):275-83. PubMed ID: 12325023
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.
Al Koudsi N; Mwenifumbo JC; Sellers EM; Benowitz NL; Swan GE; Tyndale RF
Eur J Clin Pharmacol; 2006 Jun; 62(6):481-4. PubMed ID: 16758265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
